Stivarga is a medicine used to treat colon or rectal cancer that has spread, a stomach and gut tumor called GIST, and liver cancer, after other treatments have stopped working. It is taken as a pill by mouth. It works by blocking signals that tumors use to grow and to build new blood vessels.
Every report comes from a Lived member, sent anonymously.
Have you tried Stivarga (Regorafenib) for Colorectal Cancer?
Regorafenib, sold as Stivarga, is a prescription cancer medicine taken as a tablet. It is approved for adults with three kinds of advanced cancer, in each case after specific earlier treatments have been used. In colorectal cancer that has spread to other parts of the body, it is used after the standard chemotherapy drugs (a fluorouracil-type drug, oxaliplatin and irinotecan), after a medicine that blocks tumor blood vessel growth such as bevacizumab, and after an antibody drug such as cetuximab or panitumumab if the tumor has no RAS gene mutation (these antibodies work only in tumors without that mutation). In gastrointestinal stromal tumor (GIST), a tumor that starts in the wall of the stomach or intestine, it is used when the tumor cannot be removed by surgery or has spread, and has already been treated with imatinib and sunitinib, two earlier targeted pills. In hepatocellular carcinoma, the most common form of primary liver cancer, it is used after sorafenib. Regorafenib does not cure these cancers. Its purpose is to slow the disease, and in colorectal and liver cancer, median survival in trials was a few months longer than with supportive care alone.
Cells pass growth signals along chains of enzymes called kinases, which act like switches that turn processes on. Many cancers depend on some of these switches staying on. Regorafenib is a kinase inhibitor, meaning it blocks several of these switches at once. Some of its targets help tumors build the new blood vessels they need to grow, such as the receptors for VEGF (vascular endothelial growth factor). Others, such as KIT and RAF, carry signals that push cancer cells to divide. Blocking both kinds can slow a tumor's growth, even though it seldom shrinks it. Because it acts on many targets, including ones healthy tissue relies on, it also causes predictable side effects. Reducing blood vessel signaling can raise blood pressure, increase bleeding and slow wound healing.
The standard dose is 160 mg, which is four 40 mg tablets taken together once a day for 21 days, followed by 7 days off. Each 28-day stretch is called a cycle, and cycles repeat for as long as the medicine is helping and side effects remain manageable. Take it at the same time each day, swallowed whole with water, after a low-fat meal (the label specifies under 600 calories and under 30% fat). Food changes how much of the drug the body absorbs, so this instruction matters. If a dose is missed, do not take two doses on the same day to make up for it. Dose changes are a normal part of treatment. The oncologist may pause the medicine or lower the dose in 40 mg steps, down to 80 mg a day, depending on side effects and blood test results. In colorectal cancer, a study called ReDOS tested starting at 80 mg and raising the dose by 40 mg each week toward 160 mg if side effects allowed. More people stayed on treatment long enough to start a third cycle (43% versus 26% on the standard start), with similar effect on the cancer and fewer side effects. Some oncologists use this gradual start, so ask which approach is planned.
The most characteristic side effect is hand-foot skin reaction: redness, swelling, pain or blisters on the palms and soles, often where there is pressure or friction. About half of people in the trials developed it, usually during the first cycle, and it is more common in Asian patients. Reporting it early matters, because a pause or a lower dose often lets it settle before it becomes disabling. Other common effects include tiredness, diarrhea, poor appetite and weight loss, mouth sores, a hoarse voice, rash, nausea, fever, belly or other pain, higher blood pressure and infections. High blood pressure usually appears during the first cycle. Some effects need a call to the care team right away rather than at the next visit. Yellowing of the skin or eyes, dark urine or pain in the upper right belly can signal liver injury. Severe belly pain or swelling, especially with high fever, chills or vomiting, can signal a tear in the bowel. A severe or persistent headache, vision changes, a seizure, confusion or unusual drowsiness can signal a rare brain problem. One cause is swelling in the brain brought on by the medicine. Another affects people whose liver is already damaged by liver cancer, cancer that has spread to the liver or other liver disease: ammonia can build up in the blood and affect the brain. Unusual bleeding or bruising, a widespread rash with blisters or peeling skin, and signs of infection should also be reported promptly. Call 911 for chest pain, shortness of breath, or feeling dizzy or about to pass out, which can signal a heart problem. Heavy bleeding that does not stop, such as vomiting blood or passing black stools, and a seizure that lasts more than a few minutes also need emergency help.
Regorafenib carries an FDA boxed warning, the agency's most serious, for severe and sometimes fatal liver injury. Liver blood tests are done before starting, at least every two weeks for the first two months (when most liver problems appear) and then at least monthly. If results rise, the medicine is paused, reduced or stopped. Several medicines and foods change how much regorafenib is in the body. Grapefruit juice, the antibiotic clarithromycin and antifungal medicines such as itraconazole, ketoconazole, posaconazole and voriconazole can raise levels and worsen side effects. The tuberculosis antibiotic rifampin, the seizure medicines phenytoin, carbamazepine and phenobarbital, and the herbal supplement St. John's wort can lower levels and make it less effective. These combinations should be avoided. People taking warfarin, a blood thinner, need more frequent INR checks (the INR is a blood test of how long blood takes to clot). Regorafenib can also raise levels of methotrexate (a medicine used for some cancers and for rheumatoid arthritis and psoriasis) and some cholesterol-lowering statins, such as atorvastatin. That can increase their side effects, so the prescriber may monitor or adjust those medicines. Blood pressure should be under control before treatment starts and is usually checked weekly for the first six weeks. Because it slows wound healing, regorafenib is stopped at least two weeks before planned surgery and not restarted for at least two weeks after major surgery, and only once the wound has healed. Regorafenib can seriously harm a developing baby. Women who could become pregnant and men with partners who could become pregnant should use effective contraception during treatment and for two months after the last dose, and anyone who becomes pregnant should tell the care team right away. Breastfeeding is not recommended during treatment and for two weeks after the last dose.
The first two months are the most closely watched. Expect frequent blood tests and blood pressure checks, and expect side effects such as hand-foot skin reaction to appear early if they are going to. Pauses and dose reductions are common: in the colorectal cancer trial, more than half of people needed a break from the medicine and over a third had their dose lowered. This is usually a way of staying on treatment, not a sign it has failed. Whether it is working is judged mainly with periodic scans rather than by how a person feels. Benefits are real but measured in months. In the colorectal cancer trial, the median survival (the point by which half of people had died) was 6.4 months with regorafenib versus 5.0 months without it, and tumors seldom shrank. In liver cancer the median was 10.6 versus 7.8 months. In GIST, the tumor was held in check for a median of 4.8 months versus under one month on placebo; survival was similar between groups, likely because most people on placebo switched to regorafenib once their tumor grew. Treatment continues until the cancer grows or side effects outweigh the benefit. Because the expected gain is modest and the side effects can be significant, it is reasonable to weigh quality of life openly with the oncologist and to revisit that balance as treatment goes on.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Stivarga (Regorafenib), what you've noticed, or ask the community a question.